What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Surgery
His main research concerns Internal medicine, Gastroenterology, Infliximab, Surgery and Ulcerative colitis.
His research links Placebo with Internal medicine.
His Gastroenterology research is multidisciplinary, incorporating perspectives in Colonoscopy, Intestinal mucosa and Monoclonal antibody.
His study looks at the intersection of Infliximab and topics like Malignancy with Pooled analysis and Antibody.
His Surgery research incorporates elements of Relative risk and Confidence interval.
Gary R. Lichtenstein combines subjects such as Clinical endpoint, Adverse effect and Colitis with his study of Ulcerative colitis.
His most cited work include:
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial (3357 citations)
- Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis (2790 citations)
- Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. (841 citations)
What are the main themes of his work throughout his whole career to date?
Gary R. Lichtenstein mainly investigates Internal medicine, Gastroenterology, Ulcerative colitis, Inflammatory bowel disease and Crohn's disease.
His Internal medicine study combines topics from a wide range of disciplines, such as Placebo and Surgery.
In general Gastroenterology study, his work on Colitis often relates to the realm of MMX, thereby connecting several areas of interest.
The various areas that Gary R. Lichtenstein examines in his Ulcerative colitis study include Adverse effect, Tofacitinib, Clinical trial and Maintenance therapy.
His Inflammatory bowel disease research is multidisciplinary, relying on both Azathioprine, Immunology and Intensive care medicine.
Many of his studies on Crohn's disease apply to Certolizumab pegol as well.
He most often published in these fields:
- Internal medicine (71.89%)
- Gastroenterology (46.32%)
- Ulcerative colitis (34.40%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (71.89%)
- Inflammatory bowel disease (29.32%)
- Ulcerative colitis (34.40%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Inflammatory bowel disease, Ulcerative colitis, Gastroenterology and In patient.
His study ties his expertise on Oncology together with the subject of Internal medicine.
His work investigates the relationship between Inflammatory bowel disease and topics such as Intensive care medicine that intersect with problems in MEDLINE and Guideline.
His Ulcerative colitis study is concerned with the larger field of Disease.
Disease is closely attributed to Surgery in his study.
The Gastroenterology study combines topics in areas such as Placebo and Chromoendoscopy.
Between 2016 and 2021, his most popular works were:
- ACG Clinical Guideline: Management of Crohn’s Disease in Adults (310 citations)
- ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. (185 citations)
- Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. (51 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Cancer
Gary R. Lichtenstein focuses on Internal medicine, Inflammatory bowel disease, Ulcerative colitis, Gastroenterology and Crohn's disease.
Gary R. Lichtenstein performs integrative Internal medicine and In patient research in his work.
His study in Inflammatory bowel disease is interdisciplinary in nature, drawing from both Irritable bowel syndrome, Biosimilar, Intensive care medicine, Endoscopy and Depression.
His research in Ulcerative colitis intersects with topics in Mercaptopurine, Tofacitinib, Janus kinase inhibitor, Clinical trial and Retrospective cohort study.
His Gastroenterology research includes elements of Vedolizumab and Placebo.
His Crohn's disease research integrates issues from Pharmacy, Diabetes mellitus, Adult patients and Pulmonary disease.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
